Target based drug design - A reality in virtual sphere

Current Medicinal Chemistry

Volumn 22, Issue 13, 2015, Pages 1603-1630

  Verma, Saroj ^a   Prabhakar, Yenamandra S ^a  

^a ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Drug resistance; Homology modelling; Molecular dynamics simulations; Structural vaccinology; Structure based drug design; Target based drug design; Target site identification; Virtual screening

Indexed keywords

BP 897; DOCKING PROTEIN; VACCINE;

AB INITIO CALCULATION; ANTIMALARIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CASE STUDY; CATALYSIS; CHEMICAL STRUCTURE; COMPUTER MODEL; DRUG DESIGN; DRUG RESEARCH; DRUG RESISTANCE; DRUG TARGETING; GENOME; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN STRUCTURE; ANIMAL; CHEMISTRY; COMPUTER INTERFACE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; USER-COMPUTER INTERFACE; VACCINES;

EID: 84931275453     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150209151209     Document Type: Article

References (314)

1. Ma, Q.; Lu, A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev., 2011, 63, 437-59.
2. Liao, C.; Sitzmann, M.; Pugliese, A.; Nicklaus, M.C. Software and resources for computational medicinal chemistry. Future Med. Chem., 2011, 3, 1057-85.
3. Kortagere, S.; Lill, M.; Kerrigan, J. Role of computational methods in pharmaceutical sciences. Methods Mol. Biol., 2012, 929, 21-48.
4. Brown, J.R.; Magid-Slav, M.; Sanseau, P.; Rajpal, D.K. Computational biology approaches for selecting host-pathogen drug targets. Drug Discov. Today, 2011, 16, 229-36.
5. Achenbach, J.; Tiikkainen, P.; Franke, L.; Proschak, E. Computational tools for polypharmacology and repurposing. Future Med. Chem., 2011, 3, 961-8.
6. Yao, L. In silico search for drug targets of natural compounds. Curr. Pharm. Biotechnol., 2012, 13, 1632-9.
7. Anderson, A.C. The process of structure-based drug design. Chem. Biol., 2003, 10, 787-97.
8. Harris, C.; Smith, G.H. Captopril (Capoten, E.R. Squibb & Sons). Drug Intell. Clin. Pharm., 1981, 15, 932-9.
9. Thiel, K.A. Structure-aided drug design's next generation. Nat. Biotechnol., 2004, 22, 513-9.
10. Cohen, N.C. Structure-based drug design and the discovery of Aliskiren (Tekturna): Perseverance and creativity to overcome a R&D pipeline Challenge. Chem. Biol. Drug Des., 2007, 70, 557-565.
11. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm374761.htm
12. http://www.cancernetwork.com/news/fda-approves-ibrutinibchronic-lymphocytic-leukemia
13. Pan, Z.; Scheerens, H.; Li SJ.; Schultz, B.E.; Sprengeler, P.A.; Burrill, LC.; Mendonca, R.V.; Sweeney, M.D.; Scott, K.C.; Grothaus, P.G.; Jeffery, D.A.; Spoerke, J.M.; Honigberg, L.A.; Young, P.R.; Dalrymple, S.A.; Palmer, J.T. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem. Med. Chem., 2007, 2, 58-61.
14. Kim, C.U.; Lew, W.; Williams, M.A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M.S.; Mendel, D.B.; Tai, C.Y.; Laver, W.G.; Stevens, R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc., 1997, 119, 681-690.
15. LaBonte, J.; Lebbos, J.; Kirkpatrick, P. Fresh from the pipeline: Enfuvirtide. Nat. Rev. Drug Discov., 2003, 2, 345-346.
16. Das, K.; Clark, A.D Jr.; Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L.M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J, De Corte, B.; Kavash R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pauwels, R.; De Béthune, M.P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.; Arnold, E. Roles of conformational and positional adaptability in structurebased design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem., 2004, 47, 2550-2560.
17. Ghosh, A.K.; Dawson, Z.L.; Mitsuya, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg. Med. Chem., 2007, 15, 7576-80.
18. von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov., 2007, 6, 967-74.
19. Njoroge, F.G.; Chen, K.X.; Shih, N.Y.; Piwinski, J.J. Challenges in modern drug discovery: A case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res., 2008, 41, 50-9.
20. Greer, J.; Erickson, J.W.; Baldwin, J.J.; Varney, M.D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem., 1994, 37, 1035-1054.
21. Dash, A.K.; Tyle, P. Solid-state characterization of AG337 (Thymitaq), a novel antitumor drug. J. Pharm. Sci., 1996, 85, 1123-7.
22. Rutenber, E.E.; Stroud, R.M. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity. Structure, 1996, 4, 1317-24.
23. Kaldor, S.W.; Kalish, V.J.; Davies, J.F.; Shetty, B.V.; Fritz, J.E.; Appelt, K.; Burgess, J.A.; Campanale, K.M.; Chirgadze, N.Y.; Clawson, D.K.; Dressman, B.A.; Hatch, S.D.; Khalil, D.A.; Kosa, M.B.; Lubbehusen, P.P.; Muesing, M.A.; Patick, A.K.; Reich, S.H.; Su, K.S.; Tatlock, J.H. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem., 1997, 40, 3979-85.
24. Nagar, B.; Bornmann, W.G.; Pellicena, P.; Schindler, T.; Veach, D.R.; Miller, W.T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 2002, 62, 4236-43.
25. Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem., 2010, 53, 4295-9.
26. Cui, J.J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P.P.; Pairish, M.; Jia L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R.S.; Edwards, M.P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem., 2011, 54, 6342-63.
27. Kalyaanamoorthy, S.; Chen YP. Structure-based drug design to augment hit discovery. Drug Discov. Today, 2011, 16, 831-9.
28. Schmidt, T.; Bergner, A.; Schwede, T. Modelling threedimensional protein structures for applications in drug design. Drug Discov. Today, 2014, 19, 890-897.
29. Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol., 2011, 162, 1239-49.
30. Tan H, Ge X, Xie L. Structural systems pharmacology: A new frontier in discovering novel drug targets. Curr. Drug Targets, 2013, 14, 952-8.
31. Selzer, P.M.; Brutsche, S.; Wiesner, P.; Schmid, P.; Mullner, H. Target-based drug discovery for the development of novel antiinfectives. Int. J. Med. Microbiol., 2000, 290, 191-201.
32. Govender, V.S.; Ramsugit, S.; Pillay, M. Mycobacterium tuberculosis adhesins: potential biomarkers as anti-tuberculosis therapeutic and diagnostic targets. Microbiology, 2014, 160, 1821-31.
33. Goker, M.; Klenk, H.P. Phylogeny-driven target selection for largescale genome-sequencing (and other) projects. Stand. Genomic Sci., 2013, 8, 360-74.
34. Saitou, N.; Nei, M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol., 1987, 4, 406-25. [https://www.ebi.ac.uk/Tools/phylogeny/clustalw2-phylogeny/].
35. Dereeper, A.; Guignon, V.; Blanc, G.; Audic, S.; Buffet, S.; Chevenet, F.; Dufayard, J.F.; Guindon, S.; Lefort, V.; Lescot, M.; Claverie, J.M.; Gascuel O. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res., 2008, 36, W465-9. [http://www.phylogeny.fr/version2-cgi/index.cgi].
36. Guindon, S.; Dufayard, J.F.; Lefort, V.; Anisimova, M.; Hordijk, W.; Gascuel, O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol., 2010, 59, 307-21.
37. Paterson, A.L.; Shannon, N.B.; Lao-Sirieix, P.; Ong, C.A.; Peters, C.J.; O'Donovan, M.; Fitzgerald, R.C. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut, 2013, 62, 1415-24.
38. Kanehisa, M.; Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res., 2000, 28, 27-30. [http://www.genome.jp/kegg/pathway.html].
39. Frolkis, A.; Knox, C.; Lim, E.; Jewison, T.; Law, V.; Hau, D.D.; Liu, P.; Gautam, B.; Ly, S.; Guo, A.C.; Xia, J.; Liang, Y.; Shrivastava, S.; Wishart, D.S. SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res., 2010, 38, D480-7. [http://www.smpdb.ca/].
40. Caspi, R.; Altman, T.; Billington, R.; Dreher, K.; Foerster, H.; Fulcher, C.A.; Holland, T.A.; Keseler, I.M.; Kothari, A.; Kubo, A.; Krummenacker, M.; Latendresse, M.; Mueller, L.A.; Ong, Q.; Paley, S.; Subhraveti, P.; Weaver, D.S.; Weerasinghe, D.; Zhang, P.; Karp, P.D. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res., 2014, 42, D459-71. [http://www.metacyc.org/pwy-search.shtml].
41. Gardner, M.J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R.W.; Carlton, J.M.; Pain, A.; Nelson, K.E.; Bowman, S.; Paulsen, I.T.; James, K.; Eisen, J.A.; Rutherford, K.; Salzberg, S.L.; Craig, A.; Kyes, S.; Chan, M.S.; Nene, V.; Shallom, SJ.; Suh, B.; Peterson, J.; Angiuoli, S.; Pertea, M.; Allen, J.; Selengut, J.; Haft, D.; Mather, M.W.; Vaidya, A.B.; Martin, D.M.; Fairlamb, A.H.; Fraunholz, M.J.; Roos, D.S.; Ralph, S.A.; McFadden, G.I.; Cummings, L.M.; Subramanian, G.M.; Mungall, C.; Venter, J.C.; Carucci, D.J.; Hoffman, S.L.; Newbold, C.; Davis, R.W.; Fraser, C.M.; Barrell, B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419, 498-511.
42. Vaidya, A.B.; Morrisey, J.M.; Zhang, Z.; Das, S.; Daly, T.M.; Otto, T.D.; Spillman, N.J.; Wyvratt, M.; Siegl, P.; Marfurt, J.; Wirjanata, G.; Sebayang, B.F.; Price, R.N.; Chatterjee, A.; Nagle, A.; Stasiak, M.; Charman, S.A.; Angulo-Barturen, I.; Ferrer, S.; Belen Jiménez-Diaz, M.; Martinez, M.S.; Gamo, F.J.; Avery V.M.; Ruecker A.; Delves, M.; Kirk, K.; Berriman, M.; Kortagere, S.; Burrows, J.; Fan E.; Bergman, L.W. Pyrazoleamide compounds are potent antimalarials that target Na(+) homeostasis in intraerythrocytic Plasmodium falciparum. Nat. Commun., 2014, 5, 5521.
43. Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3, 673-83.
44. Apsel, B.; Blair, J.A.; Gonzalez, B.; Nazif, T.M.; Feldman, M.E.; Aizenstein, B.; Hoffman, R.; Williams, R.L.; Shokat, K.M.; Knight, Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol., 2008, 4, 691-9.
45. De Smet, F.; Christopoulos, A.; Carmeliet, P. Allosteric targeting of receptor tyrosine kinases. Nat. Biotechnol., 2014, 32, 1113-20.
46. Conn, P.J.; Lindsley, C.W.; Meiler, J.; Niswender, C.M. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat. Rev. Drug Discov., 2014, 13, 692-708.
47. Rosano C.; Stec-Martyna E.; Lappano R.; Maggiolini M. Structurebased approach for the discovery of novel selective estrogen receptor modulators. Curr. Med. Chem., 2011, 18, 1188-94.
48. Shen, J.; Jiang, J.; Kuang, G.; Tan, C.; Liu, G.; Huang, J.; Tang, Y. Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening. Eur. J. Med. Chem., 2012, 54, 188-96.
49. Harms, J.E.; Benveniste, M.; Maclean, J.K.; Partin, K.M.; Jamieson, C. Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy. Neuropharmacology, 2013, 64, 45-52.
50. Yang, Y.; Adelstein, S.J.; Kassis, A.I. Target discovery from data mining approaches. Drug Discov. Today, 2012, 17, S16-23.
51. Ross, K.E.; Arighi, C.N.; Ren, J.; Huang, H.; Wu, C.H. Construction of protein phosphorylation networks by data mining, text mining and ontology integration: analysis of the spindle checkpoint. Database (Oxford). 2013, 2013, bat038.
52. Czarnecki, J.; Shepherd, A.J. Mining biological networks from fulltext articles. Methods Mol. Biol., 2014, 1159, 135-45.
53. Perry, A.S.; Loftus, B.; Moroose, R.; Lynch, T.H.; Hollywood, D.; Watson, R.W.; Woodson, K.; Lawler, M. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. Br. J. Cancer, 2007, 96, 1587-94.
54. Ahn, Y.Y.; Lee, D.S.; Burd, H.; Blank, W.; Kapatral, V. Metabolic network analysis-based identification of antimicrobial drug targets in category A bioterrorism agents. PLoS One, 2014, 9, e85195.
55. Sun, J.; Li, Y.; Zhao, Z. Phylogenetic profiles for the prediction of protein-protein interactions: how to select reference organisms? Biochem. Biophys. Res. Commun., 2007, 353, 985-91.
56. Yu, H.; Luscombe, N.M.; Lu, H.X.; Zhu, X.; Xia, Y.; Han, J.D.; Bertin, N.; Chung S.; Vidal M.; Gerstein M. Annotation transfer between genomes: protein-protein interologs and protein-DNA regulogs. Genome Res., 2004, 14, 1107-18.
57. Kim, W.K.; Park, J.; Suh, J.K. Large scale statistical prediction of protein-protein interaction by potentially interacting domain (PID) pair. Genome Inform., 2002, 13, 42-50.
58. Sprinzak, E.; Margalit, H. Correlated sequence-signatures as markers of protein-protein interaction. J. Mol. Biol., 2001, 311, 681-92.
59. Agarwal, S.; Liu, F.; Yu, H. Simple and efficient machine learning frameworks for identifying protein-protein interaction relevant articles and experimental methods used to study the interactions. BMC Bioinformatics. 2011, 12, S10.
60. Emamjomeh, A.; Goliaei, B.; Zahiri, J.; Ebrahimpour, R. Predicting protein-protein interactions between human and hepatitis C virus via an ensemble learning method. Mol. Biosyst., 2014, 10, 3147-54.
61. Bandyopadhyay, S.; Bagchi, A.; Maulik, U. Active site driven ligand design: an evolutionary approach. J. Bioinform. Comput. Biol., 2005, 3, 1053-70.
62. Khafizov, K.; Madrid-Aliste, C.; Almo, S.C.; Fiser, A. Trends in structural coverage of the protein universe and the impact of the Protein Structure Initiative. Proc. Natl. Acad. Sci. U. S. A., 2014, 111, 3733-8.
63. Xu, D.; Zhang, Y. Ab Initio structure prediction for Escherichia coli: towards genome-wide protein structure modeling and fold assignment. Sci. Rep., 2013, 3, 1895.
64. Krieger, E.; Nabuurs, S.B.; Vriend, G. In: Structural Bioinformatics; Philip E. Bourne and Helge Weissig, Eds.; Wiley-Liss, Inc.: Wilmington, 2003; pp. 507-521
65. Maganti, L.; Manoharan, P.; Ghoshal, N. Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein-ligand interaction studies. J. Mol. Model, 2010, 16, 1539-1547.
66. Cavasotto, C.N.; Phatak, S.S. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today, 2009, 14, 676-83.
67. Sadowski, M.I.; Jones, D.T. Benchmarking template selection and model quality assessment for high-resolution comparative modeling. Proteins: Struct. Funct. Bioinf., 2007, 69, 476-85.
68. Tapas, S.; Kumar, A.; Dhindwal, S.; Preeti.; Kumar, P. Structural analysis of chorismate synthase from Plasmodium falciparum: A novel target for antimalaria drug discovery. Int. J. Biol. Macromol., 2011, 49, 767-77.
69. Fernandez-Fuentes, N.; Rai, B.K.; Madrid-Aliste, C.J.; Fajardo, J.E.; Fiser, A. Comparative protein structure modeling by combining multiple templates and optimizing sequence-to-structure alignments. Bioinformatics, 2007, 23, 2558-65.
70. Rost, B. Twilight zone of protein sequence alignments. Protein Eng., 1999, 12, 85-94.
71. Xiang, Z. Advances in homology protein structure modeling. Curr. Protein Pept. Sci., 2006, 7, 217-27.
72. Zhu, K.; Day, T.; Warshaviak, D.; Murrett, C.; Friesner, R.; Pearlman, D. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins: Struct. Funct. Bioinf., 2014, 82, 1646-55.
73. Malkhed, V.; Gudlur, B.; Kondagari, B.; Dulapalli, R.; Vuruputuri, U. Study of interactions between Mycobacterium tuberculosis proteins: SigK and anti-SigK. J. Mol. Model, 2011, 17, 1109-19.
74. Krieger, E.; Joo, K.; Lee, J.; Lee, J.; Raman, S.; Thompson, J.; Tyka, M.; Baker, D.; Karplus, K. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins: Struct. Funct. Bioinf., 2009, 77, 114-22.
75. Raval, A.; Piana, S.; Eastwood, M.P.; Dror, R.O.; Shaw, D.E. Refinement of protein structure homology models via long, all-atom molecular dynamics simulations. Proteins: Struct. Funct. Bioinf., 2012, 80, 2071-9.
76. Lindert, S.; Meiler, J.; McCammon, J.A. Iterative Molecular Dynamics-Rosetta Protein Structure Refinement Protocol to Improve Model Quality. J. Chem. Theory Comput., 2013, 9, 3843-3847.
77. Anand, K.; Palm, G.J.; Mesters J. R.; Siddell, S. G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J., 2002, 21, 3213-3224.
78. Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J.R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science, 2003, 300, 1763-1767.
79. Takeda-Shitaka, M.; Takaya, D.; Chiba, C.; Tanaka, H.; Umeyama, H. Protein structure prediction in structure based drug design. Curr. Med. Chem., 2004, 11, 551-558.
80. Bin, X.; Chun-Shan, G.; Xiao-Ying, X.; Cheng, L.; Jing, C.; Hai-Bin, L.; Li-Li, C.; Guo-Wei, L.; Tao, S.; Chang-Ying, Y.; Li-Duo, Y.; Wen-Hu, D.; Jing-Kang, S.; Lei. Q.; T ie-Liu, S.; Yi-Xue, L.; Kai-Xian, C.; Xiao-Min, L.; Xu, S.; Jian-Hua, S.; Hua-Liang, J. A 3D model of SARS-CoV3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin., 2003, 24, 497-504.
81. Matthews, D.A.; Dragovich, P.S.; Webber, S.E.; Fuhrman, S.A.; Patick, A.K.; Zalman, L.S.; Hendrickson, T.F.; Love, R.A.; Prins, T.J.; Marakovits, J.T.; Zhou, R.; Tikhe, J.; Ford, CE.; Meador, J.W.; Ferre, R.A.; Brown, E.L.; Binford, S.L.; Brothers, M.A.; DeLisle, D.M.; Worland, S.T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 11000-11007.
82. Levoin, N.; Calmels, T.; Krief, S.; Danvy, D.; Berrebi-Bertrand, I.; Lecomte, J.M.; Schwartz, J.C.; Capet, M. Homology model versus x-ray structure in receptor-based drug design: A retrospective analysis with the dopamine D3 receptor. ACS Med. Chem. Lett., 2011, 2, 293-297.
83. Lee, J.; Wu, S.; Zhang, Y. In: From protein structure to function with bioinformatics; D.J. Rigden, Ed.; Springer, New York, 2009; pp. 3-25
84. Anfinsen, C.B. Principles that govern the folding of protein chains. Science, 1973, 181, 223-30.
85. Brooks, B.R.; Bruccoleri, R.E.; Olafson, B.D.; States, D.J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem., 1983, 4, 187-217.
86. Cornell, W.D.; Cieplak, P.; Bayly, C.; Gould, I.; Merz, K.J.; Ferguson, D.; Spellmeyer, D.; Fox, T.; Caldwell, J.; Kollman, P. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc., 1995, 117, 5179-5197.
87. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, AE.; Berendsen, H.J. GROMACS: fast, flexible, and free. J Comput Chem., 2005, 26, 1701-18.
88. Zhang, Y.; Skolnick, J. Scoring function for automated assessment of protein structure template quality. Proteins, 2004, 57, 702-10.
89. Roy, A.; Kucukural, A.; Zhang, Y. I-TASSER: A unified platform for automated protein structure and function prediction. Nat Protoc., 2010, 5, 725-38.
90. Xu, D.; Zhang, Y. Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field. Proteins, 2012, 80, 1715-35.
91. Nguyen, H.; Maier, J.; Huang, H.; Perrone, V.; Simmerling, C. Folding simulations for proteins with diverse topologies are accessible in days with a physics-based force field and implicit solvent. J. Am. Chem .Soc., 2014, 136, 13959-62.
92. Simoncini, D.; Zhang, K.Y. Efficient sampling in fragment-based protein structure prediction using an estimation of distribution algorithm. PLoS One, 2013, 8, e68954.
93. Rohl, C.A.; Strauss, C.E.; Misura, K.M.; Baker, D. Protein structure prediction using Rosetta. Methods Enzymol., 2004, 383, 66-93.
94. Wang, Z.X. A re-estimation for the total numbers of protein folds and superfamilies. Protein Eng., 1998, 11, 621-6.
95. Kelley, L.A.; Sternberg, MJ. Protein structure prediction on the Web: A case study using the Phyre server. Nat. Protoc., 2009, 4, 363-71.
96. Wu, S.; Zhang, Y. MUSTER: Improving protein sequence profileprofile alignments by using multiple sources of structure information. Proteins, 2008, 72, 547-56.
97. Jones, D.T.; Bryson, K.; Coleman, A.; McGuffin, LJ.; Sadowski, MI.; Sodhi, JS.; Ward, JJ. Prediction of novel and analogous folds using fragment assembly and fold recognition. Proteins, 2005, 61, 143-51.
98. Yan, R.X.; Si, J.N.; Wang, C.; Zhang, Z. DescFold: A web server for protein fold recognition. BMC Bioinformatics, 2009, 10, 416.
99. Holm, L.; Rosenstrom, P. Dali server: conservation mapping in 3D. Nucleic Acids Res., 2010, 38, (Web Server issue):W545-9.
100. Dismuke, W.M.; McKay, B.S.; Stamer, W.D. Myocilin, a component of a membrane-associated protein complex driven by a homologous Q-SNARE domain. Biochemistry, 2012, 51, 3606-13.
101. Yoshikawa, Y.; Oishi, S.; Kubo, T.; Tanahara, N.; Fujii, N.; Furuya, T. Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands. J. Med. Chem. 2013, 56, 4236-51.
102. Unajak, S.; Sawatdichaikul, O.; Songtawee, N.; Rattanabunyong, S.; Tassnakajon, A.; Areechon, N.; Hirono, I.; Kondo, H.; Khunrae, P.; Rattanarojpong, T.; Choowongkomon, K. Homology modeling and virtual screening for antagonists of protease from yellow head virus. J. Mol. Model, 2014, 20, 2116.
103. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins: Struct. Funct. Bioinf., 1995, 23, 318-26.
104. Combet, C.; Jambon, M.; Deléage, G.; Geourjon, C. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics, 2002, 18, 213-4.
105. Lambert, C.; Léonard, N.; De Bolle, X.; Depiereux, E. ESyPred3D: Prediction of proteins 3D structures. Bioinformatics, 2002, 18, 1250-6.
106. Schwede, T.; Kopp, J.; Guex, N.; Peitsch, M.C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res., 2003, 31, 3381-5.
107. Debe, D.A.; Danzer, J.F.; Goddard, W.A.; Poleksic, A. Structfast: protein sequence remote homology detection and alignment using novel dynamic programming and profile-profile scoring. Proteins: Struct. Funct. Bioinf., 2006, 64, 960-7.
108. Grunberg, R.; Nilges, M.; Leckner, J. Biskit-A software platform for structural bioinformatics. Bioinformatics, 2007, 23, 769-70.
109. Schymkowitz, J.; Borg, J.; Stricher, F.; Nys, R.; Rousseau, F.; Serrano, L. The FoldX web server: an online force field. Nucleic Acids Res., 2005, 33, W382-8.
110. Bates, P.A.; Kelley, L.A.; MacCallum, R.M.; Sternberg, M.J. Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins: Struct. Funct. Bioinf., 2001, Suppl 5, 39-46.
111. Nielsen, M.; Lundegaard, C.; Lund, O.; Petersen, TN. CPHmodels-3.0-remote homology modeling using structure-guided sequence profiles. Nucleic Acids Res., 2010, 38, W576-81.
112. Peng, J.; Xu, J. RaptorX: exploiting structure information for protein alignment by statistical inference. Proteins: Struct. Funct. Bioinf., 2011, 10, 161-71.
113. McGuffin, L.J.; Jones, D.T. Improvement of the Genthreader method for genomic fold recognition. Bioinformatics, 2003, 19, 874-81.
114. Soding, J.; Biegert, A.; Lupas, AN. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res., 2005, 33, W244-8.
115. Wu, S.; Zhang, Y. LOMETS: A local meta-threading-server for protein structure prediction. Nucleic Acids Res., 2007, 35, 3375-82.
116. Kurowski, M.A.; Bujnicki, J.M. GeneSilico protein structure prediction meta-server. Nucleic Acids Res. 2003, 31, 3305-7.
117. Si, J.N.; Yan, R.X.; Wang, C.; Zhang, Z.; Su, X.D. TIM-Finder: A new method for identifying TIM-barrel proteins. BMC Struct. Biol., 2009, 9, 73.
118. Kim, D.E.; Chivian, D.; Baker, D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res., 2004, 32, W526-31.
119. Hung, L.H.; Ngan, S.C.; Liu, T.; Samudrala, R. PROTINFO: new algorithms for enhanced protein structure predictions. Nucleic Acids Res., 2005, 33, W77-80.
120. Jayaram, B.; Dhingra, P.; Lakhani, B.; Shekhar, S. Bhageerath-Targeting the near impossible: Pushing the frontiers of atomic models for protein tertiary structure prediction. J. Chem. Sci., 2012, 124, 83-91.
121. DePristo, M.A.; de Bakker, PI.; Lovell, S.C.; Blundell, T.L. Ab initio construction of polypeptide fragments: efficient generation of accurate, representative ensembles. Proteins, 2003, 51, 41-55.
122. Luthy, R.; Bowie, J.U.; Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature, 1992, 356, 83-85.
123. Laskoswki, R.A.; MacArthur, M.W.; Moss, D.S.; Thorton, J.M. Procheck: A program to check the stereochemical quality of protein structures. J. Appl. Cryst., 1993, 26, 283-291.
124. Colovos, C.; Yeates, T.O. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci., 1993, 2, 1511-1519
125. Hooft, R.W.; Vriend, G.; Sander, C.; Abola, E.E. Errors in protein structures. Nature, 1996, 381, 272-272.
126. Pontius, J.; Richelle, J.; Wodak, S.J. Deviations from standard atomic volumes as a quality measure for protein crystal structures. J. Mol. Biol., 1996. 264, 121-136.
127. Laskowski, R.A.; Hutchinson, E.G.; Michie, A.D.; Wallace, A.C.; Jones, M.L.; Thornton, J.M. PDBsum: A Web-based database of summaries and analyses of all PDB structures. Trends Biochem. Sci., 1997, 22, 488-90.
128. Willard, L.; Ranjan, A.; Zhang, H.; Monzavi, H.; Boyko, R.F.; Sykes, B.D.; Wishart, D.S. Vadar: A web server for quantitative evaluation of protein structure quality. Nucleic Acids Res., 2003, 31, 3316-9.
129. Davis, I.W.; Murray, L.W.; Richardson, J.S.; Richardson, D.C. Molprobity: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res., 2004, 32, W615-9.
130. Pugalenthi, G.; Shameer, K.; Srinivasan, N.; Sowdhamini, R. Harmony: A server for the assessment of protein structures. Nucleic Acids Res., 2006, 34, W231-4.
131. Wiederstein, M.; Sippl, M.J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res., 2007, 35, W407-10.
132. Pawlowski, M.; Gajda, M.J.; Matlak, R.; Bujnicki, J.M. MetaMQAP: A meta-server for the quality assessment of protein models. B.M.C. Bioinformatics., 2008, 29, 9:403.
133. Berjanskii, M.; Liang, Y.; Zhou, J.; Tang, P.; Stothard, P.; Zhou, Y.; Cruz, J.; MacDonell, C.; Lin, G.; Lu, P.; Wishart, DS. PROSESS: A protein structure evaluation suite and server. Nucleic Acids Res., 2010, 38, W633-40.
134. Wang, Y.Y.; Nacherc, J.C.; Zhao. X.M. Predicting drug targets based on protein domains. Mol. Bio. Syst., 2012, 8, 1528-1534.
135. Marchler-Bauer, A.; Lu, S.; Anderson, J.B.; Chitsaz, F.; Derbyshire, M.K.; DeWeese-Scott, C.; Fong, J.H.; Geer, L.Y.; Geer, R.C.; Gonzales, N.R.; Gwadz, M.; Hurwitz, D.I.; Jackson, J.D.; Ke, Z.; Lanczycki, C.J.; Lu, F.; Marchler, G.H.; Mullokandov, M.; Omelchenko, M.V.; Robertson, C.L.; Song, J.S.; Thanki, N.; Yamashita, R.A.; Zhang, D.; Zhang, N.; Zheng, C.; Bryant, SH. CDD: A Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res., 2011, 39, D225-9.
136. Schomburg, I.; Chang, A.; Placzek, S.; Sohngen, C.; Rother, M.; Lang, M.; Munaretto, C.; Ulas, S.; Stelzer, M.; Grote, A.; Scheer, M.; Schomburg, D. BRENDA in 2013: integrated reactions, kinetic data, enzyme function data, improved disease classification: new options and contents in BRENDA. Nucleic Acids Res., 2013, 41, D764-72.
137. Huang, B.; Schroeder, M. LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation. B.M.C. Struct. Biol., 2006, 6, 19.
138. Laurie, A.T.; Jackson, R.M. Q-Site Finder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics, 2005, 21, 1908-1916.
139. Binkowski, T.A.; Naghibzadeh, S.; Liang, J. CASTp: computed atlas of surface topography of proteins. Nucleic Acids Res., 2003, 31, 3352-3355.
140. Sakkiah, S.; Arooj, M.; Kumar, M.R.; Eom, S.H.; Lee, K.W. Identification of inhibitor binding site in human sirtuin 2 using molecular docking and dynamics simulations. PLoS One, 2013, 8, e51429.
141. Fuzo, C.A.; Degreve, L. New pockets in dengue virus 2 surface identified by molecular dynamics simulation. J. Mol. Model, 2013, 19, 1369-77.
142. Hetényi, C.; van der Spoel D. Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett., 2006, 580, 1447-50.
143. Shan, Y.; Kim, E.T.; Eastwood, M.P.; Dror, R.O.; Seeliger, M.A.; Shaw D.E. How Does a Drug Molecule Find Its Target Binding Site. J. Am. Chem. Soc., 2011, 133, 9181-9183.
144. Miller, P.S.; Aricescu, A.R. Crystal structure of a human GABAA receptor. Nature, 2014, 512, 270-5.
145. Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des., 2011, 7, 146-57.
146. Bordogna, A.; Pandini, A.; Bonati, L. Predicting the accuracy of protein-ligand docking on homology models. J. Comput. Chem., 2011, 32, 81-98.
147. Sixto-Lopez, Y.; Gomez-Vidal, J.A.; Correa-Basurto, J. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies. Appl. Biochem. Biotechnol., 2014, 173, 1907-26.
148. Rodrigues, J.P.; Melquiond, A.S.; Karaca, E.; Trellet, M.; van Dijk, M.; van Zundert, GC.; Schmitz, C.; de Vries, S.J.; Bordogna, A.; Bonati, L.; Kastritis, P.L.; Bonvin, A.M. Defining the limits of homology modeling in information-driven protein docking. Proteins, 2013, 81, 2119-28.
149. Li, L.; Huang, Y.; Xiao, Y. How to use not-always-reliable binding site information in protein-protein docking prediction. PLoS One, 2013, 8, e75936.
150. Novoa, E. M.; Ribas de Pouplana, L.; Barril, X.; Orozco, M. Ensemble Docking from Homology Models. J. Chem. Theory Comput., 2010, 6, 2547-2557.
151. Yuriev, E.; Ramsland, PA. Latest developments in molecular docking: 2010-2011 in review. J. Mol. Recognit., 2013, 26, 215-39.
152. Ding, F.; Yin, S.; Dokholyan, NV. Rapid flexible docking using a stochastic rotamer library of ligands. J. Chem. Inf. Model, 2010, 50, 1623-32
153. Ding, F.; Dokholyan, NV. Incorporating backbone flexibility in MedusaDock improves ligand-binding pose prediction in the CSAR2011 docking benchmark. J. Chem. Inf. Model, 2013, 53, 1871-9.
154. Jain A.N. Scoring functions for protein-ligand docking. Curr. Protein Pept. Sci., 2006, 7, 407-20.
155. Mozziconacci, J.C.; Arnoult, E.; Bernard, P.; Do, Q.T.; Marot, C.; Allory, L.M. Optimization and validation of a docking-scoring protocol; application to virtual screening for COX-2 inhibitors J. Med. Chem. 2005, 48, 1055-1068.
156. Morris, GM.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30, 2785-91.
157. Sotriffer, C.A.; Flader, W.; Winger, R.H.; Rode, B.M.; Liedl, K.R.; Varga, J.M. Automated docking of ligands to antibodies: methods and applications. Methods, 2000, 20, 280-91.
158. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins: Struct. Funct. Bioinf., 2003, 52, 609-23.
159. Liebeschuetz, J.W.; Cole, J.C.; Korb, O. Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test. J. Comput. Aided Mol. Des., 2012, 26, 737-48.
160. Heurich, M.; Altintas, Z.; Tothill, I.E. Computational design of peptide ligands for ochratoxin A. Toxins (Basel), 2013, 5, 1202-18.
161. Brozell, S.R.; Mukherjee, S.; Balius, T.E.; Roe, D.R.; Case, D.A.; Rizzo, R.C. Evaluation of DOCK 6 as a pose generation and database enrichment tool. J. Comput. Aided Mol. Des., 2012, 26, 749-73.
162. Coleman, R.G.; Carchia, M.; Sterling, T.; Irwin, J.J.; Shoichet, B.K. Ligand pose and orientational sampling in molecular docking. PLoS One, 2013, 8, e75992.
163. Spitzer, R.; Jain, AN. Surflex-Dock: Docking benchmarks and realworld application. J. Comput. Aided. Mol. Des., 2012, 26, 687-99.
164. SYBYL, version 7.3 (2006) Tripos Associates, St. Louis, MO
165. Rao, S.N.; Head, M.S.; Kulkarni, A.; LaLonde, J.M. Validation studies of the site-directed docking program LibDock. J. Chem. Inf. Model, 2007, 47, 2159-71.
166. Discovery Studio, version 3.5. Accelrys, Inc; San Diego, CA, USA: 2012.
167. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47, 1739-49.
168. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49, 6177-96.
169. Wadood, A.; Jamal, S.B.; Riaz, M.; Mir A. Computational analysis of benzofuran-2-carboxlic acids as potent Pim-1 kinase inhibitors. Pharm Biol. 2014, 52, 1170-8.
170. MOE: The Molecular Operating Environment from Chemical Computing Group Inc., 1255 University St., Suite 1600, Montreal, Quebec, Canada H3B 3X3. [http://www.chemcomp.com]
171. Ermondi, G.; Caron, G.; Lawrence, R.; Longo, D. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis. J. Comput. Aided Mol. Des., 2004, 18, 683-96.
172. Hermann, J.C.; Marti-Arbona, R.; Fedorov, A.A.; Fedorov, E.; Almo, S.C.; Shoichet, B.K.; Raushel, F.M. Structure-based activity prediction for an enzyme of unknown function. Nature, 2007, 448, 775-9.
173. Schmidt, D.; Bernat, V.; Brox, R.; Tschammer, N.; Kolb, P. Identifying Modulators of CXC Receptors 3 and 4 with Tailored Selectivity Using Multi-Target Docking. ACS Chem. Biol., 2014, [Epub ahead of print]
174. Van Duyne, R.; Cardenas, J.; Easley, R.; Wu, W.; Kehn-Hall, K.; Klase, Z.; Mendez, S.; Zeng, C.; Chen, H.; Saifuddin, M.; Kashanchi, F. Effect of transcription peptide inhibitors on HIV-1 replication. Virology, 2008, 376, 308-22.
175. Lind, KE.; Du, Z.; Fujinaga, K.; Peterlin, BM.; James, TL. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol., 2002, 9, 185-93.
176. Bennani, Y.L. Drug discovery in the next decade: innovation needed ASAP. Drug Discov. Today, 2011, 16, 779-92.
177. Lavecchia, A.; Di Giovanni, C. Virtual screening strategies in drug discovery: A critical review. Curr. Med. Chem., 2013, 20, 2839-60.
178. Schneider, G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov., 2010, 9, 273-6.
179. Subramaniam, S.; Mehrotra, M.; Gupta, D. Virtual high throughput screening (vHTS)-A perspective. Bioinformation, 2008, 3, 14-7.
180. Irwin, J.J.; Shoichet, B.K. ZINC-A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model, 2005, 45, 177-82.
181. Bolton, E.E.; Wang, Y.; Thiessen, P.A.; Bryant, S.H. In: Annual Reports in Computational Chemistry; Ralph A. Wheeler and David C. Spellmeyer, Eds.; Elsevier: Oxford, UK, 2008; Vol. 4, pp. 217-240.
182. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res., 2006, 34, D668-72.
183. Bento, A.P.; Gaulton, A.; Hersey, A.; Bellis, L.J.; Chambers, J.; Davies, M.; Krüger, F.A.; Light, Y.; Mak, L.; McGlinchey, S.; Nowotka, M.; Papadatos, G.; Santos, R.; Overington, J.P. The ChEMBL bioactivity database: an update. Nucleic Acids Res., 2014, 42, D1083-90.
184. Novick, P.A.; Ortiz, O.F.; Poelman, J.; Abdulhay, A.Y.; Pande, V.S. SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery. PLoS One, 2013, 8, e79568.
185. Chen, J.H.; Linstead, E.; Swamidass, S.J.; Wang, D.; Baldi, P. ChemDB update-full-text search and virtual chemical space. Bioinformatics, 2007, 23, 2348-51.
186. Seiler, K.P.; George, G.A.; Happ, M.P.; Bodycombe, N.E.; Carrinski, HA.; Norton, S.; Brudz, S.; Sullivan, JP.; Muhlich, J.; Serrano, M.; Ferraiolo, P.; Tolliday, NJ.; Schreiber, SL.; Clemons, P.A. ChemBank: A small-molecule screening and cheminformatics resource database. Nucleic Acids Res., 2008, 36, D351-9.
187. eMolecules. https://www.emolecules.com/ (Accessed on July 15, 20014).
188. 4SC Drug company: Product in pipeline. http://www.4sc.de/product-pipeline/overview (Accessed on July 15, 20014).
189. 4SC Drug company: Technology. http://www.4sc.de/researchdevelopment/ technology%20 (Accessed on July 15, 20014).
190. Roughley, S.; Wright, L.; Brough, P.; Massey, A.; Hubbard, R.E. Hsp90 inhibitors and drugs from fragment and virtual screening. Top. Curr. Chem., 2012, 317, 61-82.
191. Nagpal, I.; Raj, I.; Subbarao, N.; Gourinath, S. Virtual screening, identification and in vitro testing of novel inhibitors of O-acetyl-Lserine sulfhydrylase ofEntamoeba histolytica. PLoS One, 2012, 7, e30305.
192. Hu, H.; Mao, S.; Bugrysheva, J.V.; Pruett, S.; Liotta, D.C.; Scott, J.R.; Snyder, J.P. Group A streptococcus inhibitors by highthroughput virtual screening. Eur. J. Med. Chem., 2014, 82C, 120-126.
193. Zhang, S.; Tan, J.; Lai, Z.; Li, Y.; Pang, J.; Xiao, J.; Huang, Z.; Zhang, Y.; Ji, H.; Lai, Y. An Effective Virtual Screening Strategy toward Covalent Ligands: Identification of Novel NEDD8-activating Enzyme Inhibitors. J. Chem. Inf. Model, 2014, 54, 1785-97.
194. Kumar, R.; Garg, P.; Bharatam, P.V. Shape-based virtual screening, docking and molecular dynamics simulations to identify Mtb-ASADH inhibitors. J. Biomol. Struct. Dyn., 2014, 1-12.
195. Ma, B.; Shatsky, M.; Wolfson, H.J.; Nussinov, R. Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations. Protein Sci., 2002, 11, 184-197.
196. Teague, S.J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov., 2003, 2, 527-541.
197. Durrant, J.D.; McCammon, J.A. Molecular dynamics simulations and drug discovery. BMC Biology, 2011, 9, 1-9.
198. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J,; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem., 2005, 26, 1781-802. [http://www.ks.uiuc.edu/Research/namd/].
199. Pronk, S.; Pall, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M.R.; Smith, J.C.; Kasson, P.M.; van der Spoel, D.; Hess, B.; Lindahl, E. GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 2013, 29, 845-54. [http://www.gromacs.org.].
200. Gale, J.D.; Rohl, A.L. "The General Utility Lattice Program," Mol. Simul., 2003, 29, 291-341. GULP:Program for performing Molecular dynamics simulations in various conditions. [http://projects.ivec.org/gulp/downloads.html] (Accessed on July 15, 20014).
201. Marsili, S.; Signorini, G.F.; Chelli, R.; Marchi, M.; Procacci, P. ORAC: A molecular dynamics simulation program to explore free energy surfaces in biomolecular systems at the atomistic level. J. Comput. Chem., 2010, 31, 1106-16. [http://www.chim.unifi.it/orac/ #toc5].
202. HOOMD-blue web page. http://codeblue.umich.edu/hoomd-blue. (Accessed on July 15, 20014).
203. Vargiu, A.V.; Ruggerone, P.; Opperman, T.J.; Nguyen, ST.; Nikaido, H. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrob Agents Chemother., 2014, 58, 6224-34.
204. Durrant, J.D; McCammon, J.A. Molecular dynamics simulations and drug discovery. BMC Biol., 2011, 9, 71.
205. Zhang, J.L.; Zheng, Q.C.; Chu, W.T.; Zhang, H.X. Drug design benefits from molecular dynamics: some examples. Curr. Comput. Aided Drug Des., 2013, 9, 532-46.
206. Kasahara, K.; Kinoshita, K.; Takagi, T. Ligand-binding site prediction of proteins based on known fragment-fragment interactions. Bioinformatics, 2010, 26, 1493-9. 'BUMBLE', is available at [http://bumble.hgc.jp/.]
207. Tang, G.W.; Altman, R.B. Knowledge-based Fragment Binding Prediction. PLoS Comput. Biol., 2014, 10, e1003589.
208. Joseph-McCarthy, D.; Campbell, A.J.; Kern, G.; Moustakas, D. Fragment-based lead discovery and design. J. Chem. Inf. Model, 2014, 54, 693-704.
209. Free, S.M Jr.; Wilson, J.W. A Mathematical Contribution to Structure-Activity Studies. J. Med. Chem., 1964, 7, 395-9.
210. Sharma, B.K.; Verma, S.; Prabhakar, Y.S. Topological and physicochemical characteristics of 1,2,3,4-Tetrahydroacridin-9(10H)-ones and their antimalarial profiles: A composite insight to the structure-activity relation. Curr. Comput. Aided Drug Des., 2013, 9, 317-35.
211. Leach, A.G.; Jones, H.D.; Cosgrove, D.A.; Kenny, P.W.; Ruston, L.; MacFaul, P.; Wood, J.M.; Colclough, N.; Law, B. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. J. Med. Chem., 2006, 49, 6672-82.
212. Posy, S.L.; Claus, B.L.; Pokross, M.E.; Johnson, S.R. 3D matched pairs: integrating ligand-and structure-based knowledge for ligand design and receptor annotation. J. Chem. Inf. Model, 2013, 53, 1576-88.
213. Griffen, E.; Leach, A.G.; Robb, G.R.; Warner, D.J. Matched molecular pairs as a medicinal chemistry tool. J. Med. Chem., 2011, 54, 7739-50.
214. Weber, J.; Achenbach, J.; Moser, D.; Proschak, E. Vammpire: A matched molecular pairs database for structure-based drug design and optimization. J. Med. Chem., 2013, 56, 5203-7.
215. Boucher, H.W. Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspective using the example of bloodstream infection as an indication. Clin. Infect. Dis., 2010, 50, S4-9.
216. Chong, C.R.; Janne, P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med., 2013, 19, 1389-400.
217. Calculation of protein isoelectric point; http://isoelectric.ovh.org/
218. Kyte, J.; Doolittle, R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol., 1982, 157, 105-132.
219. Sherry, S.T.; Ward, M.; Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res., 1999, 9, 677-9.
220. Yuan, H.Y.; Chiou, J.J.; Tseng, W.H.; Liu, C.H.; Liu, C.K.; Lin, Y.J.; Wang, H.H.; Yao, A.; Chen, Y.T.; Hsu, C.N. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res., 2006, 34, W635-41.
221. Ng, P.C.; Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res., 2003, 31, 3812-3814.
222. Cheng, J.; Randall, A.; Baldi, P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins: Struct. Funct. Bioinf., 2006, 62, 1125-32.
223. Mi, H.; Guo, N.; Kejariwal, A.; Thomas, P.D. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res., 2007, 35, D247-D252.
224. Bromberg, Y.; Yachdav, G.; Rost, B. SNAP predicts effect of mutations on protein function. Bioinformatics, 2008, 24, 2397-2398.
225. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.; Kondrashov, A.S.; Sunyaev, S.R. A method and server for predicting damaging missense mutations. Nat. Methods, 2010, 7, 248-9.
226. Teng, S.; Srivastava, A.K; and Wang, L. Sequence feature-based prediction of protein stability changes upon amino acid substitutions. BMC Genomics, 2010, 11, S5.
227. Cheng, Y.C.; Hsiao, F.C.; Yeh, E.C.; Lin, W.J.; Tang, C.Y.; Tseng, H.C.; Wu, H.T.; Liu, C.K.; Chen, C.C.; Chen, Y.T.; Yao, A. VarioWatch: providing large-scale and comprehensive annotations on human genomic variants in the next generation sequencing era. Nucleic Acids Res., 2012, 40, W76-81.
228. Reva, B.; Antipin, Y.; Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res., 2011, 39, e118.
229. Capriotti, E.; Fariselli, P.; Casadio, R. I-Mutant 2.0: Predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res., 2005, 33, 306-310.
230. Parthiban, V.; Gromiha, M.M.; Schomburg D. CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res., 2006, 34, 239-242.
231. Masso, M.; Vaisman, II. A structure-based computational mutagenesis elucidates the spectrum of stability-activity relationships in proteins. Conf. 33rd Annual International Conference of the IEEE EMBS, Boston, Massachusetts USA, August 30-September 3, 2011; pp. 3225-8.
232. Worth, C.L.; Preissner, R.; Blundell, T.L. SDM-A server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res., 2011, 39, W215-22.
233. Magyar, C.; Gromiha, M.M.; Pujadas, G.; Tusnady, G.E.; Simon, I. SRide: A server for identifying stabilizing residues in proteins. Nucleic Acids Res., 2005, 33, W303-5.
234. Walsh, I.; Minervini, G.; Corazza, A.; Esposito, G.; Tosatto, S.C.; Fogolari, F. Bluues server: electrostatic properties of wild-type and mutated protein structures. Bioinformatics, 2012, 28, 2189-90.
235. Padhi, A.K.; Jayaram, B.; Gomes, J. Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations. Sci. Rep. 2013, 1225, 1-9.
236. Zhang, J.; Hou, T.; Wang, W.; Liu, J.S. Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance. Proc. Natl. Acad. Sci., 2010, 107, 1321-1326.
237. Ge, Y.; Wu, J.; Xia, Y.; Yang, M.; Xiao, J.; Yu, J. Molecular dynamics simulation of the complex PBP-2x with drug cefuroxime to explore the drug resistance mechanism of Streptococcus suis R61. PLoS One, 2012, 7, e35941.
238. Debnath, U.; Verma, S.; Jain, S.; Katti, S.B.; Prabhakar, Y.S. Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics. J. Comput. Aided Mol. Des., 2013, 27, 637-54.
239. Ghosh, A.K.; Anderson, D.D.; Weber, I.T.; Mitsuya, H. Enhancing protein backbone binding-A fruitful concept for combating drugresistant HIV. Angew. Chem. Int. Ed. Engl., 2012, 51, 1778-802.
240. Butini, S.; Brindisi, M.; Cosconati, S.; Marinelli, L.; Borrelli, G.; Coccone, S.S.; Ramunno, A.; Campiani, G.; Novellino, E.; Zanoli, S.; Samuele, A.; Giorgi, G.; Bergamini, A.; Di Mattia, M.; Lalli, S.; Galletti, B.; Gemma, S.; Maga, G. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations. J. Med. Chem., 2009, 52, 1224-8.
241. Bailey, C.M.; Sullivan, T.J.; Iyidogan, P.; Tirado-Rives, J.; Chung, R, Ruiz-Caro, J.; Mohamed, E.; Jorgensen, W.L.; Hunter, R.; Anderson, K.S. Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy. J. Med. Chem., 2013, 56, 3959-68.
242. Cai, X.; Zhai, H.X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53, 2000-9.
243. Yu, H.; Adedoyin, A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov. Today, 2003, 8, 852-61.
244. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
245. Khan, M.T. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr. Drug. Metab., 2010, 11, 285-95.
246. Cabrera-Perez, M.A.; Pham-The, H.; Bermejo, M.; Alvarez, I.G.; Alvarez, M.G.; Garrigues, T.M. QSPR in oral bioavailability: specificity or integrality? Mini Rev. Med. Chem., 2012, 12, 534-50.
247. Sansen, S.; Yano, J.K.; Reynald, R.L.; Schoch, G.A.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem., 2007, 282, 14348-55.
248. Miley, M.J.; Zielinska, A.K.; Keenan, J.E.; Bratton, S.M.; Radominska-Pandya, A.; Redinbo, M.R. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J. Mol. Biol., 2007, 369, 498-511.
249. Lu, J.H.; Li, H.T.; Liu, M.C.; Zhang, J.P.; Li, M.; An, X.M.; Chang, W.R. Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem. Biophys. Res. Commun., 2005, 335, 417-23.
250. Ryan, A.J.; Ghuman, J.; Zunszain, P.A.; Chung, C.W.; Curry, S. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. J. Struct. Biol., 2011, 174, 84-91.
251. Nishi, K.; Ono, T.; Nakamura, T.; Fukunaga, N.; Izumi, M.; Watanabe, H.; Suenaga, A.; Maruyama, T.; Yamagata, Y.; Curry, S.; Otagiri, M. Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1∗S forms. J. Biol. Chem., 2011, 286, 14427-34.
252. Watkins, R.E.; Wisely, G.B.; Moore, L.B.; Collins, J.L.; Lambert, M.H.; Williams, S.P.; Willson, T.M.; Kliewer, S.A.; Redinbo, M.R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science, 2001, 292, 2329-33.
253. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science, 2009, 323, 1718-22.
254. O'Brien, S.E.; de Groot, M.J. Greater than the sum of its parts: combining models for useful ADMET prediction. J. Med. Chem., 2005, 48, 1287-91.
255. Zhu, T.; Cao, S.; Su, P.C.; Patel, R.; Shah, D.; Chokshi, H.B.; Szukala, R.; Johnson, M.E.; Hevener, K.E. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J. Med. Chem., 2013, 56, 6560-72. [http://www.click2drug.org/directory-ADMET.html].
256. ADMET Predictor [https://www.simulations-plus.com/Products.aspx? pID=13&lID=41] (Accessed on July 15, 2014).
257. Moda, T.L.; Torres, L.G.; Carrara, A.E.; Andricopulo, A.D. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics, 2008, 24, 2270-1.
258. Walker, T.; Grulke, CM.; Pozefsky, D.; Tropsha, A. Chembench: A cheminformatics workbench. Bioinformatics, 2010, 26, 3000-1.
259. Cheng, F.; Li, W.; Zhou, Y.; Shen, J.; Wu, Z.; Liu, G.; Lee, PW.; Tang, Y. admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. J. Chem. Inf. Model, 2012, 52, 3099-105.
260. Penta, A.; Ganguly, S.; Murugesan, S. Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase. Org. Med. Chem. Lett., 2013, 3, 1-8.
261. Lo Piparo, E.; Maunz, A.; Helma, C.; Vorgrimmler, D.; Schilter, B. Automated and reproducible read-across like models for predicting carcinogenic potency. Regul. Toxicol. Pharmacol., 2014, 70, 370-8.
262. Bhatia, S.; Schultz, T.; Roberts, D.; Shen, J.; Kromidas, L.; Marie Api, A. Comparison of cramer classification between toxtree, the OECD QSAR toolbox and expert judgment. Regul. Toxicol. Pharmacol., 2014, 71, 52-62.
263. Sharma, A.; Dutta, P.; Sharma, M.; Rajput, NK.; Dodiya, B.; Georrge, JJ.; Kholia, T; OSDD Consortium.; Bhardwaj, A. BioPhytMol: A drug discovery community resource on anti-mycobacterial phytomolecules and plant extracts. J. Cheminform., 2014, 6, 46.
264. Finco, O.; Rappuoli, R. Designing Vaccines for the Twenty-First Century Society. Front. Immunol., 2014, 5, 1-6.
265. Kaufmann, S.H.; Juliana, McElrath, M.; Lewis, D.J.; Del Giudice, G. Challenges and responses in human vaccine development. Curr. Opin. Immunol., 2014, 28C, 18-26.
266. Schubert-Unkmeir, A.; Christodoulides, M. Genome-based bacterial vaccines: current state and future outlook. BioDrugs., 2013, 27, 419-30.
267. Seib, K.L.; Zhao, X.; Rappuoli, R. Developing vaccines in the era of genomics: A decade of reverse vaccinology. Clin. Microbiol. Infect., 2012, 18, 109-16.
268. Pizza, M.; Scarlato, V.; Masignani, V.; Giuliani, M.M.; Arico, B.; Comanducci, M.; Jennings, G.T.; Baldi, L.; Bartolini, E.; Capecchi, B.; Galeotti, C.L.; Luzzi, E.; Manetti, R.; Marchetti, E.; Mora, M.; Nuti, S.; Ratti, G.; Santini, L.; Savino, S.; Scarselli, M.; Storni, E.; Zuo, P.; Broeker, M.; Hundt, E.; Knapp, B.; Blair, E.; Mason, T.; Tettelin, H.; Hood, D.W.; Jeffries, A.C.; Saunders, N.J.; Granoff, D.M.; Venter, J.C.; Moxon, E.R.; Grandi, G.; Rappuoli, R. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 2000, 287, 1816-20.
269. Esposito, S.; Castellazzi, L.; Bosco, A.; Musio, A.; Stoddard, J. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention. Immunotherapy, 2014, 6, 395-408.
270. Rappuoli, R. Vaccines, emerging viruses, and how to avoid disaster. BMC Biol., 2014, 12, 100.
271. Pruitt, K.D.; Tatusova, T.; Maglott, D.R. NCBI Reference Sequence (RefSeq): A curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res., 2005, 33, D501-4.
272. UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res., 2011, 39, D214-9.
273. He, Y.; Racz, R.; Sayers, S.; Lin, Y.; Todd, T.; Hur, J.; Li, X.; Patel, M.; Zhao, B.; Chung, M.; Ostrow, J.; Sylora, A.; Dungarani, P.; Ulysse, G.; Kochhar, K.; Vidri, B.; Strait, K.; Jourdian, G.W.; Xiang, Z. Updates on the web-based VIOLIN vaccine database and analysis system. Nucleic Acids Res., 2014, 42, D1124-32.
274. Ansari, H.R.; Flower, D.R.; Raghava, G.P. AntigenDB: an immunoinformatics database of pathogen antigens. Nucleic Acids Res., 2010, 38, D847-53.
275. Vigneron, N.; Stroobant, V.; Van den Eynde, B.J.; van der Bruggen, P. Database of T cell-defined human tumor antigens: The 2013 update. Cancer Immun., 2013, 13, 15.
276. Galagan, J.E.; Sisk, P.; Stolte, C.; Weiner, B.; Koehrsen, M.; Wymore, F.; Reddy, T.B.; Zucker, J.D.; Engels, R.; Gellesch, M.; Hubble, J.; Jin, H.; Larson, L.; Mao, M.; Nitzberg, M.; White, J.; Zachariah, Z.K.; Sherlock, G.; Ball, C.A.; Schoolnik, G.K. TB database 2010: overview and update. Tuberculosis (Edinb), 2010, 90, 225-35.
277. Al-Khedery, B.; Allred, D.R. Antigenic variation in Babesia bovis occurs through segmental gene conversion of the ves multigene family, within a bidirectional locus of active transcription. Mol. Microbiol., 2006, 59, 402-14.
278. Ponomarenko, J.; Papangelopoulos, N.; Zajonc, D.M.; Peters, B.; Sette, A.; Bourne, P.E. IEDB-3D: structural data within the immune epitope database. Nucleic Acids Res., 2011, 39, D1164-70.
279. He, Y.; Xiang, Z.; Mobley, H.L. Vaxign: The first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J. Biomed. Biotechnol., 2010, 2010, 297505.
280. Saha, S.; Raghava, G.P.S. BcePred:Prediction of Continuous BCell Epitopes in Antigenic Sequences Using Physico-chemical Properties. In: G.Nicosia, V.Cutello, P.J. Bentley and J.Timis (Eds.) ICARIS 2004, LNCS 3239, 197-204, Springer,2004.
281. Saha, S.; Bhasin, M.; Raghava, G.P. Bcipep: A database of B-cell epitopes. BMC Genomics, 2005, 6, 79.
282. Saha, S.; Raghava, G.P. Prediction methods for B-cell epitopes. Methods Mol. Biol. 2007, 409, 387-94.
283. Ansari, H.R.; Raghava, G.P. Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome. Res. 2010, 6, 6.
284. Singh, H.; Ansari, H.R.; Raghava, G.P. Improved method for linear B-cell epitope prediction using antigen's primary sequence. PLoS One, 2013, 8, e62216.
285. Gupta, S.; Ansari, H.R.; Gautam.; Raghava, G.P. Identification of B-cell epitopes in an antigen for inducing specific class of antibodies. Biol. Direct., 2013, 8, 27.
286. Larsen, J.E.; Lund, O.; Nielsen, M. Improved method for predicting linear B-cell epitopes. Immunome. Res. 2006, 2, 2.
287. Chen, J.; Liu, H.; Yang, J.; Chou, K.C. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids. 2007, 33, 423-8.
288. Giaco, L.; Amicosante, M.; Fraziano, M.; Gherardini, P.F.; Ausiello, G.; Helmer-Citterich, M.; Colizzi, V.; Cabibbo, A. B-Pred, a structure based B-cell epitopes prediction server. Adv. Appl. Bioinform. Chem., 2012, 5, 11-21.
289. B-cell Epitope Prediction Server (BCEP). This website is developed, designed and maintained by Surendra Negi, The University of Texas Medical Branch, 301 University Blv, Galveston, TX, 77555. Last updated on 5th Jan, 2014.
290. Yao, B.; Zhang, L.; Liang, S.; Zhang, C. SVMTriP: A method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity. PLoS One, 2012, 7, e45152.
291. Kulkarni-Kale, U.; Bhosle, S.; Kolaskar, A.S. CEP: A conformational epitope prediction server. Nucleic Acids Res., 2005, 33(Web Server issue):W168-71.
292. Negi, S.S.; Braun, W. Automated detection of conformational epitopes using phage display Peptide sequences. Bioinform. Biol. Insights, 2009, 3, 71-81.
293. Bhasin, M.; Raghava, G.P. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine, 2004, 22, 3195-204.
294. Larsen, M.V.; Lundegaard, C.; Lamberth, K.; Buus, S.; Lund, O.; Nielsen, M. Large-scale validation of methods for cytotoxic Tlymphocyte epitope prediction. BMC Bioinformatics, 2007, 8, 424.
295. Llano, A.; Frahm, N.; Brander, C. How to Optimally Define Optimal CytotoxicT Lymphocyte Epitopes in HIV Infection. HIV Mol. Immunol., 2009, 3-24.
296. Parker, K.C.; Bednarek, M.A.; Coligan, J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 1994, 152, 163-75.
297. Rammensee, H.; Bachmann, J.; Emmerich, N.P.; Bachor, O.A.; Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 1999, 50, 213-9.
298. Lundegaard, C.; Lamberth, K.; Harndahl, M.; Buus, S.; Lund, O.; Nielsen, M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res., 2008, 36, W509-12.
299. Cai, R.; Liu, Z.; Ren, J.; Ma, C.; Gao, T.; Zhou, Y.; Yang, Q.; Xue, Y. GPS-MBA: computational analysis of MHC class II epitopes in type 1 diabetes. PLoS One, 2012, 7, e33884.
300. Reche, P.A.; Reinherz, E.L. PEPVAC: A web server for multiepitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res., 2005, 33, W138-42.
301. Tong, J.C.; Kong, L.; Tan, T.W.; Ranganathan, S. MPID-T: database for sequence-structure-function information on T-cell receptor/ peptide/MHC interactions. Appl. Bioinf., 2006, 5, 111-4.
302. Gonzalez-Diaz, H.; Munteanu, C.R.; Postelnicu, L.; Prado-Prado, F.; Gestal, M.; Pazos, A. LIBP-Pred: web server for lipid binding proteins using structural network parameters; PDB mining of human cancer biomarkers and drug targets in parasites and bacteria. Mol. Biosyst., 2012, 8, 851-62.
303. Munteanu, C.R.; Pedreira, N.; Dorado, J.; Pazos, A.; Pérez-Montoto, L.G.; Ubeira, F.M.; Gonzalez-Diaz, H. LECTINPred: web Server that Uses Complex Networks of Protein Structure for Prediction of Lectins with Potential Use as Cancer Biomarkers or in Parasite Vaccine Design. Mol. Inf. 2014, 33, 276-285.
304. Dutta, S.; Dlugosz, L.S.; Drew, D.R.; Ge, X.; Ababacar, D.; Rovira, Y.I.; Moch, J.K.; Shi, M.; Long, C.A.; Foley, M.; Beeson, J.G.; Anders, R.F.; Miura, K.; Haynes, J.D.; Batchelor, A.H. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog., 2013, 9, e1003840.
305. Nuccitelli, A.; Cozzi, R.; Gourlay, L.J.; Donnarumma, D.; Necchi, F.; Norais, N.; Telford, JL.; Rappuoli, R.; Bolognesi, M.; Maione, D.; Grandi, G.; Rinaudo, C.D. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 10278-83.
306. Correia, B.E.; Bates, J.T.; Loomis, R.J.; Baneyx, G.; Carrico, C.; Jardine, J.G.; Rupert, P.; Correnti, C.; Kalyuzhniy, O.; Vittal, V.; Connell, M.J.; Stevens, E.; Schroeter, A.; Chen, M.; Macpherson, S.; Serra, A.M.; Adachi, Y.; Holmes, M.A.; Li, Y.; Klevit, R.E.; Graham, B.S.; Wyatt, R.T.; Baker, D.; Strong, R.K.; Crowe, J.E Jr.; Johnson, PR.; Schief, W.R. Proof of principle for epitope-focused vaccine design. Nature, 2014, 507, 201-6.
307. Lu, L.; Li, Y.; Li, S. Computational identification of potential microRNA network biomarkers for the progression stages of gastriccancer. Int. J. Data Min. Bioinform., 2011, 5, 519-31.
308. Butti, M.D .; Chanfreau, H.; Martinez, D.; Garcia, D.; Lacunza, E.; Abba, M.C. BioPlat: A software for human cancer biomarker discovery. Bioinformatics, 2014, 30, 1782-4.
309. Bjorling, E.; Lindskog, C.; Oksvold, P.; Linne, J.; Kampf, C.; Hober, S.; Uhlen, M.; Ponten, F. A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol. Cell. Proteomics, 2008, 7, 825-44.
310. Towner, R.A.; Jensen, R.L.; Vaillant, B.; Colman, H.; Saunders, D.; Giles, C.B.; Wren, J.D. Experimental validation of 5 in-silico predicted glioma biomarkers. Neuro. Oncol., 2013, 15, 1625-34.
311. Hao, J.; Serohijos, A.W.; Newton, G.; Tassone, G.; Wang, Z.; Sgroi, D.C.; Dokholyan, N.V.; Basilion, J.P. Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers. PLoS Comput. Biol. 2008, 4, e1000138.
312. Ramirez-Duran, L.A.; Rosales-Hernandez, M.C.; Hernandez-Rodriguez, M.; Mendieta-Wejebe, J.E.; Trujillo-Ferrara, J.; Correa-Basurto, J. Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations. Curr. Pharm. Des., 2013, 19, 2204-15.
313. Prabhakar, Y.S.; Gupta, M.K. Chemical Structure Indices in In Silico Molecular Design. Sci. Pharm., 2008, 76, 101-132.
314. Correa-Basurto, J.; Bello, M.; Rosales-Hernandez, M.C.; Hernandez-Rodriguez, M.; Nicolas-Vazquez, I.; Rojo-Dominguez, A.; Trujillo-Ferrara, J.G.; Miranda, R.; Flores-Sandoval, C.A. QSAR, docking, dynamic simulation and quantum mechanics studies to explore the recognition properties of cholinesterase binding sites. Chem. Biol. Interact., 2014, 209, 1-13.